AB&B BIO-TECH-B (02627) surged over 7%. As of press time, the stock climbed 7.25% to HK$50.6, with a turnover of HK$136.446 million. On the news front, AB&B BIO-TECH-B announced that the Investigational New Drug (IND) application for the Group's self-developed recombinant respiratory syncytial virus vaccine (CHO cell) (adjuvanted) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. Additionally, the IND application for this vaccine in the United States has also been approved by the U.S. Food and Drug Administration (FDA). The announcement noted that the Group's recombinant respiratory syncytial virus vaccine (CHO cell) (adjuvanted) is developed using CHO cells and can express modified pre-F protein. Through extensive screening, the Group has obtained high-yield monoclonal cell lines capable of stably expressing pre-F protein. In the Group's preclinical studies, it demonstrated higher pre-F expression levels, better thermal stability, and superior immunogenicity compared to marketed recombinant RSV vaccines.